When Should Change Notifications Be Submitted for Overseas Registration of POCT Products?

Summary

The need to submit a change notification for overseas registration of POCT products depends on the impact of the change on safety, effectiveness, and performance, as well as the regulatory requirements of the target country. Companies should first assess whether the change involves key elements such as product design, raw materials, manufacturing process, intended use, labeling, shelf life, storage conditions, packaging, or software. If the change could affect basic performance or clinical safety, a change application is typically required, and in some countries (e.g., Brazil ANVISA, Saudi SFDA) re-registration may be necessary. Companies should establish a change evaluation procedure based on GHWP member guidelines, ISO 13485, and MDSAP requirements. Core principle: any change that may affect the consistency of registration documents should be communicated in advance with the local agent or authorized representative, and technical documents (e.g., risk management report, performance verification data, clinical evaluation update) should be prepared. Common risks include: failure to declare changes leading to certificate invalidation, market ban, or fines; updated labels without proper notification causing compliance issues; delayed renewal due to failure to inform the local agent. It is recommended to establish a change classification matrix to clearly identify which changes require notification and which only need internal records, and to allow at least 6 months for processing.

Applicable Scenarios and Core Issues

When changes occur in POCT products registered overseas, the fundamental question is whether the change triggers the regulatory baseline of the target country. Different countries have varying classification standards for changes. For example, under the EU IVDR, changes may trigger a new Notified Body review; China's NMPA classifies changes into "license item changes" and "registration item changes." The core consideration is whether the change alters the intended use, technical principle, key performance indicators, or clinical risk. If so, notification is almost always required in all GHWP member countries. Common POCT product changes include: reagent formulation adjustments, calibrator traceability changes, addition of new test items, software upgrades (e.g., algorithm updates), packaging specification changes, shelf life extensions, storage temperature adjustments, etc. Some of these are minor changes (e.g., non-functional packaging changes), while others are major changes (e.g., intended use from qualitative to quantitative). The main challenge for companies is lacking a unified evaluation framework, leading to misjudgments—either reporting unnecessary changes or failing to report mandatory ones. This wastes resources and risks certificate revocation or market access restrictions. Therefore, establishing a scientific change evaluation logic is the first step toward overseas registration compliance.

Registration Evaluation Logic

Step 1: Confirm whether the product falls under the regulatory scope of medical devices or in vitro diagnostic medical devices (IVDs) in the target country. For example, Saudi Arabia's SFDA classifies POCT products as IVDs, while India's CDSCO may classify based on the test item.
Step 2: Identify the product's risk class. Most countries classify IVDs into low-risk (Class A), medium-risk (Class B/C), and high-risk (Class D). POCT products are often medium- to high-risk, such as blood glucose test strips or infectious disease test reagents. The change notification requirements vary significantly by risk class; high-risk products may require pre-approval for any change.
Step 3: Evaluate the change type. Typically, regulators divide changes into "major changes" (requiring notification) and "minor changes" (internal record only). Major changes include: changes in intended use, key raw material supplier change, major manufacturing process modifications, performance degradation, significant changes in shelf life or storage conditions, etc. Minor changes include non-functional label format adjustments, packaging color changes, etc.
Step 4: Check the reusability of existing documentation. If the company already holds NMPA registration, CE IVDR certificate, FDA 510(k) or PMA, ISO 13485, or MDSAP certification, assess whether the target country accepts these as evidence. For instance, some Southeast Asian countries accept CE technical files as a basis but require local adaptation.
Step 5: Determine the applicant. Change submission must usually be done by the local registration holder or local agent. Confirm that the agent or authorized representative in the target country is still valid to avoid delays due to agent changes.

Required Documents and Evidence

Key documents include: comparison table of technical files before and after change, rationale and necessity statement, updated risk management report (per ISO 14971), performance verification data (precision, accuracy, linearity, interference), stability studies (accelerated and real-time), clinical evaluation or performance data (if applicable), draft label comparison, packaging design change description, software version update log (if applicable), manufacturing process change description, supplier change list with new supplier qualification certificates, ISO 13485 system change records, MDSAP change notification (if applicable), confirmation letter from local agent or authorized representative, and the change application form of the target country. For GHWP member countries (e.g., China, South Korea, ASEAN countries), companies should refer to the IMDRF change classification guide. Some countries require a Certificate of Free Sale (CFS) from the country of origin after the change. Note: All documents must be provided in the official language of the target country (e.g., Arabic, Portuguese, Thai) and may require notarization or certification. For electronic submissions, pay attention to file naming conventions and size limits.

Common Mistakes

• Mistake 1: Assuming that notification is not required as long as performance is unaffected. In reality, many countries even consider label format changes as notifiable.
• Mistake 2: Judging independently without consulting the local agent. Different country agents may have different interpretations of change classification; communicate in advance.
• Mistake 3: Submitting the change notification after implementation. Most countries require pre-approval; post-hoc notification may be considered non-compliant.
• Mistake 4: Ignoring software changes. Algorithm updates, UI adjustments, and data interface changes in POCT software can affect product safety and require evaluation.
• Mistake 5: Poor version management of technical files. Failure to update technical files after changes leads to inconsistencies during audits or certificate renewals.
• Mistake 6: Neglecting multi-country registration linkages. A change in one country may trigger obligations in other countries where the product is registered; manage changes holistically.

Company Preparation Checklist

• Establish an internal change classification matrix defining notification requirements and timelines for various changes.
• Designate a person responsible for change evaluation, reviewing product changes at least quarterly.
• Sign supplementary agreements with local agents or authorized representatives to clarify change communication procedures and costs.
• Prepare change dossier templates covering change description, risk assessment, evidence summary, and approval records.
• Update change control procedures in the ISO 13485 system to align with overseas registration requirements.
• Plan timelines: major changes allow 6-12 months; minor changes allow 2-3 months.
• Retain product samples before and after change and all original verification data for regulatory spot checks.
• Sign a change declaration letter declaring the authenticity of the change and assuming legal responsibility.

AIMEILI Regulatory Interpretation and Business Impact

Companies often misjudge the "change boundary"—thinking it is an internal optimization, but inadvertently triggering re-registration. We recommend performing a "regulatory impact assessment" before initiating any change, using a change classification tool. Early in the project, companies should prioritize establishing a target country regulatory list to identify which authorities handle change approvals. Most technical documents can be reused, but clinical evaluation, label language, and stability data often need localization. The role of the local agent is often underestimated; they control certificate management and renewal, so change submissions must be confirmed through them. For multi-country registrations, companies should build a unified technical file repository, but prepare a separate change package for each country to reduce the risk of repetitive rework and corrections. Remember: change is not a one-time event; it spans the product lifecycle. Only through compliant management can market risks be truly reduced.

Frequently Asked Questions

Q: Is a packaging design change considered a major change?
Typically, if the packaging design affects product performance (e.g., sealing, moisture protection) or label content (e.g., instructions, warnings), it is a major change. If it is purely cosmetic or non-functional, most countries consider it a minor change, but it must be documented.

Q: Does adding a new test item require re-registration?
Generally yes. Adding a new test item expands the intended use, which is a major change. Typically, new performance evaluations and clinical evidence are needed. Some countries allow a supplemental application (e.g., US 510(k) special change).

Q: Can old versions continue to be sold while the change is pending approval?
It depends on the target country. Some countries allow continued sale of the old version during the change approval period (e.g., China), while others require immediate suspension of sales (e.g., Brazil ANVISA). Companies must confirm in advance and prepare transition plans.